Nemolizumab to Treat Lichen Planopilaris, a Noncontrolled, Prospective, Pilot Study.

Inclusion Criteria: * Age ≥18 years. * Clinical and/or histopathologic diagnosis of LPP. * Presence of scalp pruritus. * Average Peak Pruritus Numerical Rating Scale (PP-NRS) score ≥4 in the 7 days prior to Day 1. * Ability and willingness to provide written informed consent and comply with study procedures. * Willingness to undergo optional scalp biopsy for research purposes. Exclusion Criteria: * Other forms of alopecia that may interfere with study assessments. * Any systemic disease associated with hair loss. * Inflammatory or infectious scalp disease that may interfere with the study. * Any other conditions associated with pruritus. * Prior use of nemolizumab. * Current treatment with systemic or topical JAK inhibitors or biologics (unless appropriate washout period completed; minimum 12 weeks). * Current treatment with DMARDs (unless appropriate washout period completed; minimum 12 weeks). * Prior treatment failure of scarring alopecia with systemic or topical JAK inhibitors or * biologics. * Current treatment with topical or intralesional corticosteroids (unless appropriate washout period completed; minimum 4 weeks). * Any other current treatments for hair loss (e.g., oral/topical minoxidil, PRP) unless stable for at least 6 months or 3 months washout completed. * Allergy or hypersensitivity to nemolizumab or any excipients. * Pregnancy or unwillingness to use highly effective contraception. * Any medical condition that, in the opinion of the investigator, may interfere with study participation or interpretation of results.